VCAM1 and hypertensive disorder: Axitinib, a TKI used to treat advanced renal cell carcinoma with profound HTN as a side effect in over 50% of patients [31], strongly suppressed LEENE and eNOS expression, while inducing VCAM1 expression, both in HUVECs and in mouse aortic rings cultured ex vivo (Figure 5B,C).